Skip to main content

Ascendis Pharma A/S 6-K, filed Nov 12, 2026

Ascendis Pharma A/S (ASND)

6-K 2026-11-12 For: 2026-11-12
View Original
Added on November 12, 2026

About this 6-K

Ascendis Pharma A/S filed this 6-K on November 12, 2026.

Ascendis Pharma A/S reported product revenue of €366 million, up +89% Y/Y for the third quarter ended September 30, 2026. Positive CHMP and COMP opinions recommended TransCon CNP EU marketing authorization, with a final EC decision expected in Q4 2026. AI summary